Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
ALKS Quote, Financials, Valuation and Earnings
Last price:
$32.00
Seasonality move
:
-3.38%
Day range:
$31.87 - $33.03
52-week range:
$25.17 - $36.32
Dividend yield:
0%
P/E ratio:
15.84x
P/S ratio:
3.54x
P/B ratio:
3.05x
Volume:
1.6M
Avg. volume:
2M
1-year change:
-10.81%
Market cap:
$5.3B
Revenue:
$1.6B
EPS (TTM):
$2.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
$380.4M | $0.43 | 19.01% | 133.23% | $43.75 |
|
ASRT
Assertio Holdings, Inc.
|
$6.2M | -$1.80 | -80.74% | -9.4% | $39.94 |
|
AVDL
Avadel Pharmaceuticals Plc
|
$79.2M | $0.18 | 48.49% | -76.67% | $21.83 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.2B | $6.51 | 10.99% | 109.38% | $219.40 |
|
KRYS
Krystal Biotech, Inc.
|
$105.1M | $1.61 | 28.58% | 15.42% | $306.56 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
$32.02 | $43.75 | $5.3B | 15.84x | $0.00 | 0% | 3.54x |
|
ASRT
Assertio Holdings, Inc.
|
$11.87 | $39.94 | $76.2M | -- | $0.00 | 0% | 4.42x |
|
AVDL
Avadel Pharmaceuticals Plc
|
$21.64 | $21.83 | $2.1B | 299.90x | $0.00 | 0% | 8.56x |
|
CRMD
CorMedix, Inc.
|
$7.17 | $14.86 | $564.9M | 3.49x | $0.00 | 0% | 2.41x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$168.72 | $219.40 | $10.3B | 15.09x | $0.00 | 0% | 2.48x |
|
KRYS
Krystal Biotech, Inc.
|
$283.29 | $306.56 | $8.2B | 41.39x | $0.00 | 0% | 21.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
3.97% | 0.553 | 1.45% | 3.09x |
|
ASRT
Assertio Holdings, Inc.
|
29.83% | 1.399 | 53.04% | 1.43x |
|
AVDL
Avadel Pharmaceuticals Plc
|
27.56% | 0.412 | 2.52% | 2.14x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.201 | 67.81% | 1.24x |
|
KRYS
Krystal Biotech, Inc.
|
0.76% | -0.723 | 0.13% | 9.28x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
$341.2M | $89.1M | 20.4% | 22.16% | 22.6% | $84.4M |
|
ASRT
Assertio Holdings, Inc.
|
$30.2M | $12.9M | -18.41% | -25.86% | 26.09% | -$4.8M |
|
AVDL
Avadel Pharmaceuticals Plc
|
$80.5M | $1.9M | -0.23% | -0.34% | 2.5% | $23.2M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
KRYS
Krystal Biotech, Inc.
|
$99M | $44.3M | 19.06% | 19.22% | 41.33% | $75.4M |
Alkermes Plc vs. Competitors
-
Which has Higher Returns ALKS or ASRT?
Assertio Holdings, Inc. has a net margin of 21% compared to Alkermes Plc's net margin of 23.14%. Alkermes Plc's return on equity of 22.16% beat Assertio Holdings, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B ASRTAssertio Holdings, Inc.61.01% $1.61 $150.8M -
What do Analysts Say About ALKS or ASRT?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 36.63%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $39.94 which suggests that it could grow by 236.46%. Given that Assertio Holdings, Inc. has higher upside potential than Alkermes Plc, analysts believe Assertio Holdings, Inc. is more attractive than Alkermes Plc.
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 ASRTAssertio Holdings, Inc.3 0 0 -
Is ALKS or ASRT More Risky?
Alkermes Plc has a beta of 0.454, which suggesting that the stock is 54.612% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.775, suggesting its less volatile than the S&P 500 by 22.468%.
-
Which is a Better Dividend Stock ALKS or ASRT?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or ASRT?
Alkermes Plc quarterly revenues are $394.2M, which are larger than Assertio Holdings, Inc. quarterly revenues of $49.5M. Alkermes Plc's net income of $82.8M is higher than Assertio Holdings, Inc.'s net income of $11.4M. Notably, Alkermes Plc's price-to-earnings ratio is 15.84x while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.54x versus 4.42x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.54x 15.84x $394.2M $82.8M ASRTAssertio Holdings, Inc.4.42x -- $49.5M $11.4M
-
Which has Higher Returns ALKS or AVDL?
Avadel Pharmaceuticals Plc has a net margin of 21% compared to Alkermes Plc's net margin of 0.03%. Alkermes Plc's return on equity of 22.16% beat Avadel Pharmaceuticals Plc's return on equity of -0.34%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B AVDLAvadel Pharmaceuticals Plc90.66% $0.00 $135.6M -
What do Analysts Say About ALKS or AVDL?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 36.63%. On the other hand Avadel Pharmaceuticals Plc has an analysts' consensus of $21.83 which suggests that it could grow by 0.89%. Given that Alkermes Plc has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Avadel Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 AVDLAvadel Pharmaceuticals Plc0 5 0 -
Is ALKS or AVDL More Risky?
Alkermes Plc has a beta of 0.454, which suggesting that the stock is 54.612% less volatile than S&P 500. In comparison Avadel Pharmaceuticals Plc has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.392%.
-
Which is a Better Dividend Stock ALKS or AVDL?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Avadel Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or AVDL?
Alkermes Plc quarterly revenues are $394.2M, which are larger than Avadel Pharmaceuticals Plc quarterly revenues of $77.5M. Alkermes Plc's net income of $82.8M is higher than Avadel Pharmaceuticals Plc's net income of $20K. Notably, Alkermes Plc's price-to-earnings ratio is 15.84x while Avadel Pharmaceuticals Plc's PE ratio is 299.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.54x versus 8.56x for Avadel Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.54x 15.84x $394.2M $82.8M AVDLAvadel Pharmaceuticals Plc8.56x 299.90x $77.5M $20K
-
Which has Higher Returns ALKS or CRMD?
CorMedix, Inc. has a net margin of 21% compared to Alkermes Plc's net margin of 49.9%. Alkermes Plc's return on equity of 22.16% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ALKS or CRMD?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 36.63%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 107.21%. Given that CorMedix, Inc. has higher upside potential than Alkermes Plc, analysts believe CorMedix, Inc. is more attractive than Alkermes Plc.
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 CRMDCorMedix, Inc.4 0 0 -
Is ALKS or CRMD More Risky?
Alkermes Plc has a beta of 0.454, which suggesting that the stock is 54.612% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock ALKS or CRMD?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or CRMD?
Alkermes Plc quarterly revenues are $394.2M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Alkermes Plc's net income of $82.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Alkermes Plc's price-to-earnings ratio is 15.84x while CorMedix, Inc.'s PE ratio is 3.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.54x versus 2.41x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.54x 15.84x $394.2M $82.8M CRMDCorMedix, Inc.2.41x 3.49x $104.3M $108.6M
-
Which has Higher Returns ALKS or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of 21% compared to Alkermes Plc's net margin of 22.33%. Alkermes Plc's return on equity of 22.16% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About ALKS or JAZZ?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 36.63%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $219.40 which suggests that it could grow by 30.04%. Given that Alkermes Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 JAZZJazz Pharmaceuticals Plc9 1 0 -
Is ALKS or JAZZ More Risky?
Alkermes Plc has a beta of 0.454, which suggesting that the stock is 54.612% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.986%.
-
Which is a Better Dividend Stock ALKS or JAZZ?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or JAZZ?
Alkermes Plc quarterly revenues are $394.2M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Alkermes Plc's net income of $82.8M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Alkermes Plc's price-to-earnings ratio is 15.84x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.54x versus 2.48x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.54x 15.84x $394.2M $82.8M JAZZJazz Pharmaceuticals Plc2.48x 15.09x $1.1B $251.4M
-
Which has Higher Returns ALKS or KRYS?
Krystal Biotech, Inc. has a net margin of 21% compared to Alkermes Plc's net margin of 47.99%. Alkermes Plc's return on equity of 22.16% beat Krystal Biotech, Inc.'s return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B KRYSKrystal Biotech, Inc.92.39% $1.70 $1.2B -
What do Analysts Say About ALKS or KRYS?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 36.63%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $306.56 which suggests that it could grow by 8.21%. Given that Alkermes Plc has higher upside potential than Krystal Biotech, Inc., analysts believe Alkermes Plc is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 KRYSKrystal Biotech, Inc.10 0 0 -
Is ALKS or KRYS More Risky?
Alkermes Plc has a beta of 0.454, which suggesting that the stock is 54.612% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.
-
Which is a Better Dividend Stock ALKS or KRYS?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or KRYS?
Alkermes Plc quarterly revenues are $394.2M, which are larger than Krystal Biotech, Inc. quarterly revenues of $107.1M. Alkermes Plc's net income of $82.8M is higher than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Alkermes Plc's price-to-earnings ratio is 15.84x while Krystal Biotech, Inc.'s PE ratio is 41.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.54x versus 21.79x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.54x 15.84x $394.2M $82.8M KRYSKrystal Biotech, Inc.21.79x 41.39x $107.1M $51.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
